Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Jim Cramer Says This Is A Terrific Stock

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rapid7, Inc. (NASDAQ: RPD) doesn’t make money, so he will not go for it.

Benzinga

Fastenal And 2 Other Stocks Insiders Are Buying

Although the Nasdaq Composite gained more than 150 points on Friday, there were a few notable insider trades.

Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Elon Musk Wants You To Watch 'Idiocracy'

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk went on Twitter to share his thoughts about many of his friends not having kids.

Benzinga

Leaked Report Says Amazon May Run Out Of People To Hire In US by 2024

According to a new report, a leaked Amazon.com, Inc (NASDAQ: AMZN) internal memo from mid-2021 suggests that the company may face a resource crunch and may run out of people to hire at the company's U.S.

Benzinga

Here's How Much Someone Just Paid To Have Lunch With Warren Buffett

Someone submitted a winning bid of $19,000,100 to have lunch with Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B) CEO Warren Buffett during the final eBay Inc (NASDAQ:

Benzinga

Benzinga Bulls And Bears Of The Week: Tesla, Netflix, General Motors, Disney And A Company Betting Big On Bitcoin

Benzinga has examined the prospects for many investors' favorite stocks over the past week, while offering a 24/7 news feed, live chat and charting software on Benzinga Pro.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

CLSN: OVATION 2 Study 85% Enrolled…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Benzinga

EXCLUSIVE: Benzinga's 2022 Esports Listmakers Are Driving Gaming Forward

Financial media and data company Benzinga is capitalizing on its mission to bridge the gap between retail and institutional investors by holding free virtual events featuring speakers from innovative companies.

Benzinga

Regeneron Pharmaceuticals Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

Benzinga

This Is What Whales Are Betting On Lucid Gr

A whale with a lot of money to spend has taken a noticeably bullish stance on Lucid Gr. Looking at options history for Lucid Gr (NASDAQ:LCID) we detected 27 strange trades.

Benzinga

Check Out What Whales Are Doing With MELI

A whale with a lot of money to spend has taken a noticeably bearish stance on MercadoLibre. Looking at options history for MercadoLibre (NASDAQ:MELI) we detected 36 strange trades.

Benzinga

Pinduoduo Whale Trades For June 17

Someone with a lot of money to spend has taken a bullish stance on Pinduoduo (NASDAQ:PDD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gores Guggenheim Soars As Polestar Merger Approaches: Here's How The EV SPAC Looks

Gores Guggenheim Inc (NASDAQ: GGPI) was soaring up more than 13% on Friday, heavily outpacing the general market, which saw the S&P 500 trading up about 0.7%.

Benzinga

Cannabis Movers & Shakers: 22nd Century Group, Houseplant, Proven Media

22nd Century Group Names New CFO 22nd Century Group (NASDAQ: XXII) has appointed f R. Hugh Kinsman to oversee its financial department. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.

Benzinga

Vita Coco CFO Kevin Benmoussa Steps Down

Vita Coco Company Inc (NASDAQ:COCO) said its Chief Financial Officer Kevin Benmoussa would depart the company later in 2022. Kevin is likely to pursue an expanded finance and executive role outside of the beverage industry. However, he will remain at The Vita Coco Company until August 31 to complete the second-quarter reporting activity. The…

Benzinga

Elon Musk Just Exercised Stock Options In This Company — And No It Wasn't Tesla

The world’s richest person owns stakes in Tesla Inc (NASDAQ: TSLA), SpaceX, Twitter Inc (NYSE: TWTR) and several other companies.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Dow Jumps Over 100 Points; Crude Oil Down 7%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Friday.

Benzinga

Rivian Automotive Plans To Construct Wind Turbine At Illinois Campus

Rivian Automotive Inc (NASDAQ:RIVN) plans to establish a large-scale wind turbine at its Normal manufacturing campus in Illinois. The automaker expects to generate clean energy to enable new R1 vehicles to be powered by renewables for their first charge. Rivian installed a 783-kilowatt solar canopy in early 2022, which is scheduled to begin…

Benzinga

Lucid Group Opens Retail Studio In Colorado

Electric car maker Lucid Group Inc (NASDAQ:LCID) has opened its first studio location in Denver, Colorado, at the Cherry Creek Shopping Center. The studio marks twenty-seven studios and service center locations open in North America. The Lucid Studio in Cherry Creek will be open to the public on June 18. "The state of…

Benzinga

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

Benzinga

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

Benzinga

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors. BMO writes that Graphite's platform is expected to be safer than existing…

1 … 439 440 441 442

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.